Anti-CD320 Autoantibodies and Central Nervous System Vitamin B 12 Deficiency in Idiopathic Myelopathy
John V. Pluvinage, David Acero-Garces, Giacomo Greco, Carson E. Moseley, Sukhman Sidhu, Kelsey C. Zorn, Sravani Kondapavulur, Sonam Mohan, John Neely, Stefano Masciocchi, Pietro Businaro, Alexis García Sarreón, Ariadna Gifreu Fraixinó, Krista McCutcheon, Colette Caspar, Richard Dela Rosa, Colin Zamecnik, Asritha Tubati, Andoni I. Asencor, Madina Tugizova, Felicia Chow, Alexandra Galati, Yair Mina, Camilo Toro, Min Kang, Chu-Yueh Guo, Sarah F. Wesley, Kathryn Kvam, Sydney Lee, Ahmed Abdelhak, Thomas Martin, Yun-Han Huang, Sarah B. Berman, Jenny Linnoila, John Engstrom, Andrew McCaddon, Ari J. Green, Ralph Green, Bruce A.C. Cree, Stephen L. Hauser, Joseph L. DeRisi, Samuel J. Pleasure, Jeffrey M. Gelfand, Gary Álvarez Bravo, Matteo Gastaldi, Carlos A. Pardo, Michael R. Wilson, , , , Megan Richie, Vanja Douglas, Maulik Shah, Elan L. Guterman, Avindra Nath, Catherine G. Suen, Martineau Louine, Leah Zuroff, Josiah Gerdts, Mary Karalius, Alyssa Nylander, Carolyn Bevan, Max Liu, Iyas Daghlas, Leena Suleiman, Todd Nguyen, Benjamin Meyer, Karen IbarraImportance
Disorders affecting the spinal cord (myelopathies) can cause severe disability. Despite diagnostic advances, approximately 12% to 18% of myelopathy cases continue to elude an etiological diagnosis, hampering effective treatment.
Objective
To describe a novel autoantibody associated with idiopathic myelopathy (IM) and report its clinical, radiographic, and metabolic characteristics.
Design, Setting, and Participants
This retrospective case-control study was conducted from May 2014 to October 2025 at 4 tertiary care centers. Biofluids from 148 patients diagnosed with IM were evaluated based on clinical evidence of myelopathy without an identified etiology. Biofluids from patients with other neurological diseases (ONDs; n = 32) or known autoimmune myelitis (n = 30) were used for comparison. Proteomewide phage display was used to discover novel autoantibodies. Targeted immunoassays were used to screen for a candidate autoantibody. Downstream metabolites were measured in the cerebrospinal fluid (CSF).
Exposure
Autoantibody status.
Main Outcomes and Measures
Prevalence, clinical phenotype, CSF profile, and magnetic resonance imaging pattern of autoantibody-positive IM.
Results
Autoantibodies targeting the transcobalamin receptor (CD320) responsible for cellular transport of vitamin B
12
were identified in 18 of 32 individuals with IM (56%) in a discovery cohort (mean [SD] age, 54 [14] years; 19 male). Bioactive vitamin B
12
concentration was decreased in the CSF of individuals with positive anti-CD320 test results compared with that of control individuals with ONDs (mean [SD], 15.1 [2.3] pmol/L vs 22.9 [10.7] pmol/L;
Conclusions and Relevance
In this study, autoimmune vitamin B 12 central deficiency was associated with IM. Screening for anti-CD320 antibodies followed by metabolic confirmation of a CNS-restricted vitamin B 12 deficiency may be considered in the diagnostic evaluation of myelopathy.